Status:
COMPLETED
DCE CT/MRI Scanning Study in Patients With Solid Tumours (AstraZeneca and Royal Marsden Hospital Imaging Study)
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Royal Marsden NHS Foundation Trust
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is being carried out in patients with advanced solid tumours to assess which of two different types of imaging scans best measures activity of an experimental drug called Cediranib. The stu...
Eligibility Criteria
Inclusion
- Histologically confirmed metastatic tumour which is refractory to standard therapies
- At least one lesion size ≥3cm on in longest diameter suitable for repeat assessment by DCE-CT and DCE-MRI
- Patients must be able to undergo DCE-CT and DCE-MRI scanning procedures
- Life expectancy of at least 12 weeks
Exclusion
- Patients with hormone refractory prostate cancer (HRPC)
- Patients with a history of poorly controlled high blood pressure
- Ineligibility for MRI scanning or DCE-CT or DCE-MRI scanning
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2010
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT00748891
Start Date
August 1 2008
End Date
November 1 2010
Last Update
July 1 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
London, United Kingdom